Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Esperion (ESPR) Stock Price & Analysis
1,289 Followers
ESPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $3.40
Previous Close$1.95
Volume7.35M
Average Volume (3M)6.33M
Market Cap
$332.31M
Enterprise Value$516.24M
Total Cash (Recent Filing)$82.25M
Total Debt (Recent Filing)$266.17M
Price to Earnings (P/E)-0.9
Beta1.13
Next Earnings
May 08, 2024EPS Estimate
$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding185,052,705
10 Day Avg. Volume6,909,107
30 Day Avg. Volume6,329,491
Standard Deviation0.26
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.79
Price to Sales (P/S)3.10
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.44
Enterprise Value/Gross Profit4.44
Enterprise Value/Ebitda-3.47
Forecast
1Y Price Target
$7.41Price Target Upside280.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Esperion News
Bulls Say, Bears Say
Bulls Say
Financial OutlookWith the anticipation of profitability and a sustainable financial outlook, the company is poised for a positive shift in its revenue trajectory, bolstered by its strategic commercial expansion plans.
Market ExpansionExpansion of the total addressable market to approximately 70 million patients with the new label approval positions the company to capture a larger share of the market and potentially increase sales.
Regulatory ApprovalFDA approval of label expansions for NEXLETOL/NEXLIZET includes new indications for cardiovascular risk reduction and LDL-C lowering in a broader patient population, marking a significant milestone for the company.
Bears Say
Competitive PositionThere's caution around bempedoic acid's ability to capture meaningful market share due to strong competition and established alternatives.
Financial ChallengesMaximizing the impact of this positive label may take some significant marketing muscle at a time when Esperion is cash-strapped.
Product Market PenetrationCapturing meaningful share may not be straightforward in the primary prevention market due to underutilization of generic and more effective statins.
---
Ownership Overview
7.93% Insiders
13.02% Mutual Funds
13.28% Other Institutional Investors
65.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.70 and its highest was $3.40 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is May 08, 2024 which is in 15 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Feb 27, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.018.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is $0.05.
How many shares outstanding does Esperion have?
Esperion has 170,417,790 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went up 10.266%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Platinum Investment Management. It holds Esperion’s shares valued at 8M.
---
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.41 (280.00% Upside)
$7.41 (280.00% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 237.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 16.7%
Last 30 Days ▲ 16.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.00%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q4 2024
0:00 / 0:00
---
ESPR Stock 12 Months Forecast
Average Price Target
$7.41
▲(280.00% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
+25.32%
reiterated a buy rating 30 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of +25.32% per trade.
---